Isolated ipsilateral local recurrence of breast cancer: predictive factors and prognostic impact

[1]  R. Rouzier,et al.  Lymph node positivity in different early breast carcinoma phenotypes: a predictive model , 2019, BMC Cancer.

[2]  G. Houvenaeghel,et al.  Survival after breast cancer local recurrence according to therapeutic strategies. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[3]  C. Hudis,et al.  21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer , 2017, Breast Cancer Research and Treatment.

[4]  S. Siesling,et al.  Patterns and predictors of first and subsequent recurrence in women with early breast cancer , 2017, Breast Cancer Research and Treatment.

[5]  E. Darai,et al.  Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study , 2017, Breast Cancer Research and Treatment.

[6]  J. Bellon,et al.  The Impact of Reexcision and Residual Disease on Local Recurrence Following Breast-Conserving Therapy , 2017, Annals of Surgical Oncology.

[7]  Per Karlsson,et al.  Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  R. Rouzier,et al.  Prognostic Impact of Time to Ipsilateral Breast Tumor Recurrence after Breast Conserving Surgery , 2016, PloS one.

[9]  S. Linn,et al.  10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study. , 2016, The Lancet. Oncology.

[10]  R. Rouzier,et al.  Survival impact and predictive factors of axillary recurrence after sentinel biopsy. , 2016, European journal of cancer.

[11]  H. Kuerer,et al.  Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy , 2016, Annals of Surgical Oncology.

[12]  L. Holmberg,et al.  Progression of breast cancer following locoregional ipsilateral recurrence: importance of interval time , 2015, British Journal of Cancer.

[13]  Se Kyung Lee,et al.  Independent Prognostic Factors for Overall Survival after Salvage Operation for Ipsilateral Breast Tumor Recurrence Following Breast-Conserving Surgery , 2015, Journal of breast cancer.

[14]  Wei Shi,et al.  Identification of a Low-Risk Luminal A Breast Cancer Cohort That May Not Benefit From Breast Radiotherapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Maarten J. IJzerman,et al.  Survival after Locoregional Recurrence or Second Primary Breast Cancer: Impact of the Disease-Free Interval , 2015, PloS one.

[16]  M. Piccart,et al.  Maastricht Delphi consensus on event definitions for classification of recurrence in breast cancer research. , 2014, Journal of the National Cancer Institute.

[17]  J. Griggs,et al.  Margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Gelber,et al.  Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. , 2014, The Lancet. Oncology.

[19]  M. Clemons,et al.  Evolution of sites of recurrence after early breast cancer over the last 20 years: implications for patient care and future research , 2013, Breast Cancer Research and Treatment.

[20]  A. Luini,et al.  Repeating Conservative Surgery after Ipsilateral Breast Tumor Reappearance: Criteria for Selecting the Best Candidates , 2012, Annals of Surgical Oncology.

[21]  K. Hunt,et al.  Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy , 2012, Breast Cancer Research.

[22]  P. Fasching,et al.  Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D. Genovesi,et al.  Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study. , 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[24]  T. Nielsen,et al.  Breast cancer subtypes and the risk of local and regional relapse. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Lesperance,et al.  Validation of a web-based predictive nomogram for ipsilateral breast tumor recurrence after breast conserving therapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Funda Meric-Bernstam,et al.  High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  S. O'toole,et al.  Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[29]  J. Costantino,et al.  Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  T. Major,et al.  Prognosis of patients with local recurrence after mastectomy or conservative surgery for early-stage invasive breast cancer. , 2008, Breast.

[31]  Barbara L. Smith,et al.  Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  S. Pocock,et al.  Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. , 2007, Annals of internal medicine.

[33]  S. Pocock,et al.  Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration , 2007, PLoS medicine.

[34]  S. Bull,et al.  Analysis of incidence and prognostic factors for ipsilateral breast tumour recurrence and its impact on disease-specific survival of women with node-negative breast cancer: a prospective cohort study , 2006, Breast Cancer Research.

[35]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[36]  C. Geyer,et al.  Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  J. Coebergh,et al.  The prognosis of patients with local recurrence more than five years after breast conservation therapy for invasive breast carcinoma. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[38]  R. Collins,et al.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[39]  Umberto Veronesi,et al.  Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. , 2002, The New England journal of medicine.

[40]  B. E. F. Isher,et al.  Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. , 2002 .

[41]  Frédérique Penault-Llorca,et al.  [Immunochemistry evaluation of HER2 status in infiltration breast cancer: technical protocol and interpretation guidelines]. , 2002, Annales de pathologie.

[42]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[43]  C. Redmond,et al.  Significance of ipsilateral breast tumour recurrence after lumpectomy , 1991, The Lancet.

[44]  T. Julian,et al.  21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy , 2017, Journal of the National Cancer Institute.

[45]  A. Niemierko,et al.  Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy , 2016, Breast Cancer Research and Treatment.